Browsing Tag
Intra-Cellular Therapies
4 posts
Johnson & Johnson’s Caplyta delivers rapid Phase III bipolar mania response
The once-daily medicine reduced manic symptoms by significantly more than placebo and doubled the clinical response rate, advancing a potential new indication for a drug acquired with Intra-Cellular Therapies.
FDA gives CAPLYTA the go-ahead for major depressive disorder, boosting hopes for better remission rates
Find out how CAPLYTA’s FDA approval for major depressive disorder could redefine depression treatment and improve remission outcomes.
Johnson & Johnson to acquire Intra-Cellular Therapies in $14.6bn deal
Johnson & Johnson has announced its largest biotech acquisition in over a year, agreeing to purchase Intra-Cellular Therapies…
Breakthrough in mental health treatment: Intra-Cellular’s Caplyta emerges as a beacon of hope for schizophrenia patients
In a significant development for schizophrenia management, Intra-Cellular Therapies has announced impressive outcomes from a late-stage, Phase III…